Abstract:

In recent years, the incidence of gynecological malignancies such as cervical cancer, endometrial cancer, and ovarian cancer has been increasing, gradually extending to younger populations and posing a serious threat to women's life and health. Although standardized treatments have benefited some patients, challenges such as strong tumor heterogeneity, high rates of recurrence and metastasis, and drug resistance persist, resulting in suboptimal overall prognosis. There is an urgent need to identify novel molecular targets for precise therapy and prognostic evaluation. Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a molecule that maintains cellular membrane homeostasis and lipid metabolic balance. It is highly expressed in cervical cancer, endometrial cancer, and ovarian cancer, promoting tumor cell proliferation, migration, and invasion through pathways such as phospholipid metabolism, epithelial-mesenchymal transition, ferroptosis, and cholesterol metabolism. LPCAT1 is closely associated with high tumor invasiveness, metastasis, and poor prognosis. In-depth investigation into the molecular mechanisms and clinical applications of LPCAT1, particularly inhibitory strategies targeting LPCAT1, is expected to provide important support for early diagnosis, prognosis evaluation, and targeted therapy of gynecological malignancies.

Key words: Lysophosphatidylcholines, Acyltransferases, Genital neoplasms, female, Molecular targeted therapy, Lipid metabolism